Canadian Cancer Trials Group Bulletins

General


Trial Activation

Canadian Cancer Trials Group IND.208 -- A Phase I/II Study of the PI3 Kinase Inhibitor BKM120 given in Combination with Panitumumab in Patients with Metastatic or Advanced Ras Wild-type Colorectal Cancer -- was centrally activated May 1, 2012.